(1S,12S,14R)-14-hydroxy-9-(2H3)methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-4-ium-4-olate

• ChemBase编号: 169567
• 分子式: C17H21NO4
• 平均质量: 303.35294
• 单一同位素质量: 303.14705816
• SMILES: c12c3C[N+](CC[C@@]41C=C[C@@H](C[C@@H]4Oc2c(cc3)OC)O)(C)[O-]
• Canonical SMILES: COc1ccc2c3c1O[C@@H]1[C@]3(C=C[C@@H](C1)O)CC[N+](C2)([O-])C
• InChI: InChI=1S/C17H21NO4/c1-18(20)8-7-17-6-5-12(19)9-14(17)22-16-13(21-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-,18?/m0/s1
• InChIKey: LROQBKNDGTWXET-FVWDGWMTSA-N

名称和登记号

名称

• IUPAC标准名: (1S,12S,14R)-14-hydroxy-9-(^2H₃)methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0^1,^1^2.0^6,^1^7]heptadeca-6(17),7,9,15-tetraen-4-ium-4-olate
• IUPAC传统名: (1S,12S,14R)-14-hydroxy-9-(^2H₃)methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0^1,^1^2.0^6,^1^7]heptadeca-6(17),7,9,15-tetraen-4-ium-4-olate
• 别名: (4aS,6R,8aS,11R)-4a,5,9,10,11,12-Hexahydro-3-(methoxy-d3)-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol 11-Oxide; Nivalin-d3 Oxide; Galanthamine-d3 10-Oxide; Galanthamine-d3 β-N-Oxide; Galanthamine-O-methyl-d3 N-Oxide

登记号

• PubChem SID: 162263699
• PubChem CID: 46780423

理论计算性质

• Acid pKa: 14.810369
• 质子受体: 4
• 质子供体: 1
• LogD (pH = 5.5): 0.038566273
• LogD (pH = 7.4): 0.038666327
• Log P: 0.03866762
• 摩尔折射率: 84.3498 cm^3
• 极化性: 31.799473 Å^3
• 极化表面积: 65.57 Å^2
• 可自由旋转的化学键: 1
• 里宾斯基五规则: true

详细说明

Toronto Research Chemicals - G188527

A labelled metabolite of Galanthamine (G188500), a selective acetylcholinesterase inhibitor.

参考文献

• Bickel, U., et al.: Clin. Pharmacol. Ther., 50, 420 (1991)
• Mannens, G., et al.: Drug Metab. Dispos., 30, 553 (1991)
• Zhao, Q., et al.: J. Clin. Pharmacol., 42, 428 (1991)
• Geerts, H., et al.: Brain Res., 1033, 186 (1991)